ASPIRE-LAKEWOOD HOLDINGS INC
ASBPNASDAQTrading Snapshot
- Day Range
- $8.39 β $8.64
- 52-Week Range
- $0.11 β $562.80
- Volume
- $3.04B
- Avg Volume
- $2.36B
- Shares Outstanding
- 115,372
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $6,202
- Last Q Revenue
- $63,103
- P/E Ratio
- -1.1
- P/S Ratio
- 10.0x
- EPS (TTM)
- $-10.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +6399.8%
Why Investors Own ASBP
- βHigh-growth profile β revenue up +42.8% YoY with expanding US Equity exposure.
- βHealthy economics β 27% gross margin and 23% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ASPIRE-LAKEWOOD HOLDINGS INC
ASBPAbout ASPIRE-LAKEWOOD HOLDINGS INC
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
Brings total authorized repurchase to $10 million Reflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunity Increased authorization su

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc."

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at S

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets

Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% β Time to Buy?
Shares of Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP - Get Free Report) rose 10.9% on Monday. The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares changed hands during trading, a decline of 49% fr

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)
High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMBβ’ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMBβ’'s commitment to delivering fast-